JOURNAL OF HEALTHCARE SCIENCES

Volume 6 Issue 6 2026, Article ID: JOHS2026001240

http://dx.doi.org/10.52533/JOHS.2026.60603

e-ISSN: 1658-8967

Review

Nocturnal Hypoglycemia in Adults with Intensive Insulin Therapy

Marwah Yakoop Abdullah[1*], Raghad Ali Alsufyani[2], Ahlam Yahya Alyami[3], Thamer Hassan Aljabr[4], Dina Talal Saqa[5], Samar Izzeldin Ahmed[6], Zahraa Faez Ali[7], Fahad Ayed Albaqami[8], Abdulelah Mutlaq Alotaibi[9], Faisal Mansour Alrowili[8]

[1] *Family Medicine Consultant, East Jeddah Hospital, Jeddah, Saudi Arabia*
[2] *Department of Family Medicine, Ministry of Health, Taif, Saudi Arabia*
[3] *Department of Internal Medicine, King Khalid Hospital, Najran, Saudi Arabia*
[4] *Department of Internal Medicine, King Hamad University Hospital, Almuharraq, Bahrain*
[5] *Alajaweed Primary Healthcare, Ibn Sina National College for Medical Specialties, Jeddah, Saudi Arabia*
[6] *School of Pharmacy, Ahfad University for Women, Khartoum, Sudan*
[7] *College of Medicine, Mansoura University, Mansoura, Egypt*
[8] *College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia*
[9] *Family Medicine Diabetes Mellitus PHC, Ministry of Health, Riyadh, Saudi Arabia*

Correspondence should be addressed **Marwah Yakoop Abdullah**, Family Medicine Consultant, East Jeddah Hospital, Jeddah, Saudi Arabia. Email: marwahyq@gmail.com

Received: 19 May 2026, Accepted: 03 June 2026, Published: 14 June 2026.

Abstract

Nocturnal hypoglycemia is a frequent and clinically significant complication among adults undergoing intensive insulin therapy for diabetes mellitus. Tight glycemic control remains essential for reducing the long-term vascular complications of diabetes; however, intensive insulin regimens substantially increase the risk of hypoglycemic episodes during sleep. Nocturnal events are often prolonged and asymptomatic because physiological counterregulatory mechanisms and autonomic warning responses are diminished during sleep. Recurrent nocturnal hypoglycemia contributes to impaired hypoglycemia awareness, glycemic instability, reduced treatment adherence, and increased risk of severe complications including seizures, cardiac arrhythmias, and cognitive dysfunction. The endocrine basis of nocturnal hypoglycemia involves defective glucagon secretion, impaired sympathoadrenal activation, altered hepatic glucose production, and persistent circulating exogenous insulin levels. Circadian hormonal variation, evening physical activity, alcohol intake, renal impairment, and inconsistent carbohydrate consumption further influence overnight glucose regulation. Pharmacologic factors also play a central role, particularly the pharmacokinetic variability of insulin formulations and the timing of basal insulin administration. Long-acting insulin analogues and ultra-long-acting basal preparations have demonstrated improved glycemic stability and lower nocturnal hypoglycemia risk compared with traditional insulin therapies. Psychological consequences are highly prevalent among insulin-treated adults experiencing recurrent nocturnal hypoglycemia. Fear of nighttime episodes may lead to anxiety, sleep disturbances, emotional distress, and intentional maintenance of elevated glucose levels to avoid hypoglycemia. Family members and caregivers may also experience psychological burden associated with overnight monitoring and emergency concerns. Technological advancements including continuous glucose monitoring, sensor-augmented insulin pumps, predictive low-glucose suspend systems, and hybrid closed-loop insulin delivery have significantly improved detection and prevention of nocturnal hypoglycemia. Integration of individualized insulin optimization, diabetes education, behavioral support, and emerging automated technologies continues to improve patient safety and quality of life while supporting effective glycemic management in adults receiving intensive insulin therapy.

Keywords: *Nocturnal hypoglycemia, Intensive insulin therapy, Continuous glucose monitoring, Insulin analogues, Diabetes mellitus*

Introduction

Nocturnal hypoglycemia remains one of the most challenging complications of intensive insulin therapy in adults with diabetes mellitus. Intensive glycemic control is essential for reducing the long-term microvascular and macrovascular complications associated with diabetes, particularly in individuals with type 1 diabetes and insulin-treated type 2 diabetes. However, tighter glucose targets substantially increase the risk of hypoglycemic episodes, especially during sleep when physiological counterregulatory responses are diminished and symptom recognition is impaired (1). Episodes occurring at night are frequently underrecognized because patients may remain asymptomatic or fail to awaken during hypoglycemia, leading to prolonged periods of low blood glucose and potentially severe consequences.

The pathophysiology of nocturnal hypoglycemia involves a complex interaction between exogenous insulin administration, impaired glucagon secretion, attenuated sympathoadrenal responses, and altered hepatic glucose production. During sleep, autonomic warning symptoms such as palpitations, tremors, and sweating may be blunted, reducing the patient's ability to detect falling glucose levels. Recurrent episodes may further contribute to hypoglycemia-associated autonomic failure, thereby increasing susceptibility to future severe hypoglycemia (2, 3). Additional risk factors include missed meals, excessive evening insulin dosing, physical activity performed late in the day, alcohol consumption, renal impairment, and inconsistent dietary intake.

Pharmacological management plays a central role in determining the frequency and severity of nocturnal hypoglycemia. Traditional insulin formulations, particularly neutral protamine Hagedorn (NPH) insulin, are associated with variable absorption profiles and pronounced nocturnal insulin peaks that predispose patients to overnight glucose declines. The introduction of long-acting insulin analogues such as insulin glargine, detemir, and degludec has improved glycemic stability and reduced nocturnal hypoglycemia risk compared with older insulin preparations (3). Continuous subcutaneous insulin infusion and advancements in continuous glucose monitoring systems have further transformed diabetes care by enabling real-time glucose tracking, predictive alarms, and automated insulin suspension during impending hypoglycemia.

Beyond physiological consequences, nocturnal hypoglycemia also has important psychological and psychiatric implications. Fear of hypoglycemia is common among individuals receiving intensive insulin therapy and may lead to anxiety, sleep disturbances, impaired quality of life, and intentional maintenance of higher blood glucose levels to avoid nocturnal episodes. Family members and caregivers may also experience emotional distress related to concerns about severe nighttime events. Repeated hypoglycemia has additionally been associated with mood changes, cognitive impairment, and reduced treatment adherence, creating barriers to optimal diabetes management (4)

Methodology

Nocturnal hypoglycemia continues to present a major obstacle in achieving optimal glycemic control among adults receiving intensive insulin therapy. Although intensive insulin regimens improve long-term metabolic outcomes, they also increase the frequency of asymptomatic nocturnal glucose fluctuations that often remain undetected until severe neuroglycopenic symptoms occur (5). Physiological counterregulatory responses during sleep are substantially reduced, particularly the sympathoadrenal response, which limits the patient's ability to recognize and correct falling glucose levels. Repeated nocturnal episodes may contribute to hypoglycemia unawareness, creating a cycle of recurrent hypoglycemia and increasing vulnerability to severe events. The widespread adoption of continuous glucose monitoring (CGM) systems has improved identification of nocturnal hypoglycemia and demonstrated that these episodes occur more frequently than previously recognized through conventional self-monitoring methods (6).

http://dx.doi.org/10.52533/JOHS.2026.60603

Endocrine Basis of Nocturnal Hypoglycemia

Nocturnal hypoglycemia develops through a complex disturbance in normal glucose counterregulation during sleep, particularly in individuals receiving intensive insulin therapy. Under physiological conditions, declining plasma glucose concentrations trigger a sequence of hormonal responses involving suppression of endogenous insulin secretion, increased glucagon release, activation of the sympathoadrenal system, and stimulation of cortisol and growth hormone secretion. In insulin-treated diabetes, these protective mechanisms become progressively impaired, especially in patients with long disease duration and recurrent hypoglycemic exposure (7). Exogenous insulin continues to circulate despite falling glucose concentrations because injected insulin lacks the rapid feedback regulation characteristic of endogenous pancreatic secretion. Persistent insulin activity overnight suppresses hepatic gluconeogenesis and glycogenolysis, promoting prolonged nocturnal glucose decline.

The endocrine abnormalities associated with type 1 diabetes are particularly relevant during sleep. Glucagon responses to hypoglycemia are often markedly reduced or absent, largely because of pancreatic alpha-cell dysfunction and defective intra-islet signaling. Catecholamine responses may initially compensate for impaired glucagon secretion; however, repeated hypoglycemic episodes blunt adrenergic activation and contribute to hypoglycemia-associated autonomic failure (8). Reduced epinephrine release lowers hepatic glucose output and weakens neurogenic warning symptoms, increasing the likelihood of severe nocturnal events without patient awareness. Sleep itself further attenuates sympathoadrenal activity, creating a physiological environment in which hypoglycemia may persist for several hours before spontaneous correction occurs.

Circadian hormonal variation also contributes to nocturnal glucose instability. Growth hormone secretion increases during early nocturnal sleep and can transiently induce insulin resistance, whereas cortisol concentrations gradually rise in the early morning hours. Variability in these endocrine patterns influences overnight glucose trends and may partially explain fluctuations in nocturnal insulin requirements between individuals. Intensive insulin regimens that fail to account for these physiological rhythms may predispose patients to nocturnal hypoglycemia, particularly when long-acting insulin formulations exhibit peak activity during vulnerable sleep periods (9). Physical activity performed in the evening can amplify insulin sensitivity for several hours after exercise, increasing glucose utilization overnight and reducing hepatic glucose production. Alcohol intake exerts similar effects through inhibition of gluconeogenesis, thereby intensifying the risk of delayed nocturnal hypoglycemia. Continuous glucose monitoring studies have demonstrated that nocturnal hypoglycemia frequently occurs without recognizable symptoms and often remains substantially underreported in routine clinical practice. Prolonged exposure to low glucose concentrations during sleep has been associated with arrhythmogenic potential, cognitive dysfunction, impaired sleep quality, and increased fear of hypoglycemia among insulin-treated adults (10).

Pharmacologic Management and Insulin Optimization

Pharmacologic approaches to reducing nocturnal hypoglycemia focus primarily on optimizing insulin pharmacokinetics while maintaining adequate overnight glycemic control. Intensive insulin therapy often requires a balance between preventing fasting hyperglycemia and avoiding excessive insulin exposure during sleep. Traditional basal preparations such as NPH insulin are associated with pronounced absorption variability and a distinct peak effect several hours after administration, frequently coinciding with the middle of the night. This pharmacodynamic profile contributes substantially to nocturnal hypoglycemia risk, particularly in patients receiving evening doses or intensified basal-bolus regimens (11). Variability in insulin absorption from subcutaneous tissue, influenced by injection site, temperature, and local blood flow, may further complicate overnight glucose stability.

http://dx.doi.org/10.52533/JOHS.2026.60603

Long-acting basal insulin analogues have transformed modern diabetes management because of their flatter and more predictable activity profiles. Insulin glargine and insulin detemir demonstrate lower rates of nocturnal hypoglycemia compared with NPH insulin, largely due to reduced peak insulin activity and longer duration of action (12). Ultra-long-acting preparations such as insulin degludec provide even greater pharmacokinetic stability, allowing lower glycemic variability across a 24-hour period. Reduced day-to-day variability has particular relevance in adults with recurrent nighttime hypoglycemia or impaired hypoglycemia awareness. Clinical trials comparing basal insulin analogues with conventional insulin formulations consistently report fewer nocturnal episodes while maintaining similar glycated hemoglobin targets.

Rapid-acting insulin analogues also influence nocturnal glucose regulation. Delayed gastric emptying, inconsistent carbohydrate intake, or inaccurate prandial insulin dosing may lead to late postprandial hypoglycemia extending into sleeping hours. Careful adjustment of evening bolus insulin based on meal composition, physical activity, and bedtime glucose measurements is often required in patients using intensive regimens. Continuous subcutaneous insulin infusion offers greater flexibility by enabling individualized basal rate programming during vulnerable nocturnal periods. Temporary basal reductions may be implemented after exercise or alcohol intake to minimize delayed overnight glucose decline (13).

Technological integration has become increasingly important in pharmacologic optimization. Sensor-augmented insulin pumps equipped with predictive low-glucose suspend functions can automatically interrupt insulin delivery when glucose levels approach hypoglycemic thresholds. Hybrid closed-loop systems combine continuous glucose monitoring with algorithm-driven insulin modulation, reducing both frequency and duration of nocturnal hypoglycemia without compromising overall glycemic control (14). These systems have demonstrated particular benefit in adults with unstable glucose patterns and recurrent severe hypoglycemia, especially during prolonged sleep intervals when symptom recognition is limited.

Psychiatric and Psychological Impact

Nocturnal hypoglycemia exerts a substantial psychological burden on adults undergoing intensive insulin therapy, influencing emotional wellbeing, treatment behaviors, and daily functioning. Fear of hypoglycemia is particularly common among individuals who have previously experienced severe nighttime episodes involving confusion, seizures, or loss of consciousness. Anticipatory anxiety may persist long after the event itself, leading patients to intentionally maintain elevated bedtime glucose concentrations in an effort to avoid recurrence (15). Such behavioral adaptations can compromise glycemic targets and increase long-term risk of diabetes-related complications. Sleep-related fear is often intensified by the unpredictability of nocturnal glucose fluctuations and the inability to recognize symptoms while asleep.

Disturbed sleep quality represents a frequent consequence of recurrent nocturnal hypoglycemia. Patients may experience repeated awakenings, night sweats, nightmares, palpitations, or morning fatigue following overnight glucose decline. Continuous glucose monitoring alarms, although beneficial for safety, may also contribute to sleep fragmentation and emotional exhaustion in some individuals. Chronic sleep disruption has important psychiatric implications because inadequate sleep is closely associated with anxiety disorders, depressive symptoms, irritability, impaired concentration, and reduced coping capacity in people with diabetes (16). Mood disturbances may become more pronounced in patients with hypoglycemia unawareness, where uncertainty regarding nighttime safety generates persistent psychological distress.

The social and interpersonal effects of nocturnal hypoglycemia are also considerable. Family members and caregivers frequently report heightened anxiety related to monitoring overnight glucose levels and responding to potential emergencies. Partners may alter sleeping habits

http://dx.doi.org/10.52533/JOHS.2026.60603

because of concern regarding nocturnal seizures or severe hypoglycemic episodes. Emotional strain within households can emerge from repeated nighttime interruptions and constant vigilance surrounding diabetes management. Adults living alone often describe fear of unattended nocturnal hypoglycemia, especially in individuals with prior severe episodes or impaired awareness of falling glucose levels (17).

Cognitive function may also be influenced by recurrent nocturnal hypoglycemia. Prolonged exposure to low glucose concentrations during sleep has been associated with impaired memory, reduced psychomotor performance, and diminished executive functioning. Recurrent episodes may affect work productivity, decision-making capacity, and treatment adherence. Psychological burnout related to intensive insulin therapy can develop gradually, particularly when patients perceive diabetes management as mentally exhausting or emotionally overwhelming. Feelings of frustration, helplessness, and reduced confidence in self-management may contribute to insulin omission or avoidance of intensive glucose control strategies. Continuous glucose monitoring systems and structured psychological interventions have shown benefit in reducing fear of hypoglycemia and improving quality of life among insulin-treated adults (18).

Prevention and Emerging Technologies

Strategies aimed at preventing nocturnal hypoglycemia have evolved considerably with advances in diabetes technology and individualized insulin management. Traditional prevention methods relied heavily on bedtime glucose testing, scheduled nighttime monitoring, carbohydrate supplementation, and conservative insulin dose adjustments. Although these measures remain clinically relevant, they often fail to detect asymptomatic nocturnal glucose decline or rapidly changing glucose patterns during sleep. CGM has substantially altered this landscape by providing real-time glucose measurements, trend analysis, and programmable alerts that allow earlier recognition of impending hypoglycemia (19). Detection of nocturnal episodes through CGM has revealed that overnight hypoglycemia occurs more frequently and for longer durations than previously recognized using intermittent fingerstick monitoring.

Sensor-augmented insulin pump therapy has further improved prevention efforts by integrating glucose monitoring with automated insulin delivery adjustments. Low-glucose suspend systems temporarily interrupt basal insulin infusion when glucose concentrations fall below predefined thresholds, thereby limiting the severity and duration of nocturnal hypoglycemia. Predictive low-glucose suspend technology extends this capability by using glucose trend algorithms to anticipate impending hypoglycemia before it occurs. Clinical studies have demonstrated reductions in nocturnal hypoglycemia exposure without significant deterioration in glycated hemoglobin levels or increased risk of diabetic ketoacidosis (20). Such systems are particularly valuable in adults with hypoglycemia unawareness or recurrent severe episodes during sleep.

Hybrid closed-loop systems represent a major advancement in intensive insulin therapy. These systems continuously adjust insulin delivery based on real-time CGM readings through adaptive control algorithms that respond dynamically to glucose fluctuations. Overnight glucose regulation has shown marked improvement with hybrid closed-loop therapy because basal insulin administration can be reduced automatically during periods of falling glucose concentrations. Adults using these systems often demonstrate increased time within target glucose range and lower incidence of nocturnal hypoglycemia compared with conventional insulin pump therapy (21). Improvements in sensor accuracy, wireless connectivity, and algorithm responsiveness continue to enhance clinical performance and user confidence.

Preventive approaches also involve structured patient education and behavioral interventions. Education regarding carbohydrate intake, alcohol consumption, physical activity timing, and insulin dose modification remains essential for reducing nighttime glucose instability. Evening exercise

http://dx.doi.org/10.52533/JOHS.2026.60603

requires particular attention because increased insulin sensitivity may persist for several hours after activity and precipitate delayed nocturnal hypoglycemia. Remote glucose monitoring and smartphone-linked CGM applications have expanded caregiver involvement and facilitated rapid response to severe overnight events. Emerging research into bihormonal artificial pancreas systems incorporating glucagon delivery has generated interest because these devices may provide additional protection against hypoglycemia through automated counterregulatory hormone replacement during falling glucose levels (22).

Conclusion

Nocturnal hypoglycemia remains a significant challenge in adults receiving intensive insulin therapy because of its complex endocrine, pharmacologic, and psychological implications. Advances in insulin analogues, continuous glucose monitoring, and automated insulin delivery systems have improved overnight glycemic safety and reduced hypoglycemia burden. Individualized treatment strategies combined with patient education and psychological support are essential for optimizing long-term diabetes management. Continued innovation in diabetes technology and precision-based insulin therapy may further minimize nocturnal hypoglycemia while preserving effective glycemic control. Disclosure

Conflict of interest

There is no conflict of interest.

Funding

No funding.

Ethical consideration

No considerations.

Data availability

All data is available within the manuscript.

Author contribution

All authors contributed to conceptualizing, data drafting, collection and final writing of the manuscript.

References

1. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocrine practice. 2003;9(6):530-43.
2. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2009;94(3):709-28.
3. Bradley MC, Chillarige Y, Lee H, Wu X, Parulekar S, Muthuri S, et al. Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin. JAMA Internal Medicine. 2021;181(5):598-607.
4. Siamashvili M, Davis HA, Davis SN. Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness. Expert Review of Endocrinology & Metabolism. 2021;16(6):281-93.
5. Graveling AJ, Frier BM. The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes research and clinical practice. 2017;133:30-9.
6. Olafsdottir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes technology & therapeutics. 2018;20(4):274-84.
7. McCall AL. Insulin therapy and hypoglycemia. Endocrinology and metabolism clinics of North America. 2012;41(1):57.
8. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. New England Journal of Medicine. 2013;369(4):362-72.
9. Brunton SA. Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. Medscape General Medicine. 2007;9(2):38.
10. Mathieu C. Minimising hypoglycaemia in the real world: the challenge of insulin. Diabetologia. 2021;64(5):978-84.
11. Home P. The pharmacokinetics and pharmacodynamics of rapid-acting insulin

http://dx.doi.org/10.52533/JOHS.2026.60603

analogues and their clinical consequences. Diabetes, Obesity and Metabolism. 2012;14(9):780-8.
12. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes care. 2000;23(5):639-43.
13. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. The Journal of Clinical Endocrinology & Metabolism. 2009;94(3):729-40.
14. Peters A, Ahmann A, Battelino T, Evert A, Hirsch I, Murad M, et al. Erratum: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline (J Clin Endo Metab (2016) 101: 11 (3922-3937. Journal of Clinical Endocrinology and Metabolism. 2023;108(5):E201.
15. Gonder-Frederick L, Nyer M, Shepard JA, Vajda K, Clarke W. Assessing fear of hypoglycemia in children with type 1 diabetes and their parents. Diabetes Management (London, England). 2011;1(6):627.
16. Martyn-Nemeth P, Quinn L, Penckofer S, Park C, Hofer V, Burke L. Fear of hypoglycemia: influence on glycemic variability and self-management behavior in young adults with type 1 diabetes. Journal of Diabetes and its Complications. 2017;31(4):735-41.
17. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. Journal of medical economics. 2011;14(5):646-55.
18. Polonsky WH, Hessler D. What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users. Diabetes technology & therapeutics. 2013;15(4):295-301.
19. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes care. 2019;42(8):1593-603.
20. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. Jama. 2013;310(12).
21. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. New England Journal of Medicine. 2019;381(18):1707-17.
22. Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. New England Journal of Medicine. 2014;371(4):313-25.

http://dx.doi.org/10.52533/JOHS.2026.60603